IIMC

Immunocore is a commercial-stage biotechnology company pioneering a novel class of T cell receptor (TCR) bispecific immunotherapies known as ImmTAX. The company's lead product, KIMMTRAK (tebentafusp-tebn), is the first TCR therapeutic to receive FDA approval and is indicated for the treatment of metastatic uveal melanoma. Immunocore's proprietary platform is designed to redirect and activate T cells to recognize and kill diseased cells, including those in cancer, infectious diseases, and autoimmune disorders. The company maintains a robust pipeline with multiple programs in clinical development, including brenetafusp (IMC-F106C) for various solid tumors and candidates for HIV and HBV functional cures. Headquartered in the United Kingdom, Immunocore continues to expand its global commercial footprint while advancing its next-generation TCR-based modalities.